Cancer Research Month: SBRT Shows Effectiveness for Early-Stage Lung Cancer

May is recognized as National Cancer Research Month by The American Association for Cancer Research in an effort to bring national attention to innovative cancer research advancing the fight against the disease.

One recent study focused on stereotactic body radiation therapy (SBRT) demonstrated effectiveness for early-stage lung cancer, a common type of cancer that affects many, particularly those who smoke.

Analysis of data from the 2014 study reveals excellent long-term, local control for medically inoperable, early stage lung cancer patients treated with (SBRT. From 2003 to 2012, 300 patients with a total of 340 lesions were treated with SBRT. According to the data collected, only 13 percent of patients treated with SBRT had any form of toxicity related to the treatment throughout the 10-year study. These results provide significant evidence and support for SBRT as a viable treatment option for early-stage lung cancer.

“We have been privileged in demonstrating that lung SBRT can now be considered the standard of care for medically inoperable patients with early stage lung cancer,” said Dr. Gregory M.M Videtic, lead study author.

To learn more about this study and read the full results, click here. For more information on CyberKnife SBRT for lung cancer, view our presentation.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.